Wasdell, a UK-based packaging and manufacturing provider in the UK, has opened a quality control laboratory in Dundalk to analyze products for its pharmaceutical clientele.
The temporary medicines unit built for the agency's Central Intravenous Additive Service can produce up to 2,600 syringes weekly to meet growing demand
Adaptate gains access to Iontas’ platform to select antibodies with optimal biophysical properties for the development of gamma delta T-cell modulating therapeutics.
In Vivo Research Services has developed a 3D visualization technology that provides direct imaging data in real-time, aiming to reduce drug development time and costs.
SGS’ completed the ₤8.7m expansion of its large molecule testing facility in Glasgow and made room to increase its existing biosafety service and PCR platform capabilities.
Ligand Pharmaceuticals enters an agreement with Genagon to provide access to its drug development platform capable of producing fully human antibodies.
AAPS PharmSci 360 is a new conference this year, created in response to a desire for “fresh science,” specifically with chemical and biomolecular components. So what can you expect?
Velesco Pharma has expanded its analytical research and development capabilities to meet a growing demand for its services after acquiring a new facility in Michigan.
This year’s DIA Global Annual Meeting will focus on the latest global trends and showcase the "diverse group of key individuals driving the life science ecosystem forward," says DIA Americas managing director.
Following on from the success of last year's survey, Outsourcing-Pharma is running another 'state of the industry' survey to gauge views about the current state of the pharmaceutical contract services industry.
The non-clinical contract research organization (CRO) Citoxlab Group has acquired Solvo Biotechnology, a CRO specializing in drug transporters studies and the assessment of drug-drug interactions (DDI).
Charles River has made several expansions across the globe, including a new, 73,000 square-foot facility in Wayne, PA, which doubles its laboratory footprint in the state.
With fewer global mid-sized contract research organizations (CRO) through consolidation, some stakeholders are expressing concern that the industry could become a monopoly – “we may be getting there,” one expert said.
Scientist.com is working to implement an improved contractual landscape ahead of GDPR implementation in May, in order to ensure global compliance among sponsors and CROs.
Charles River has been granted commercial access to AstraZeneca’s high-throughput screening (HTS) and compound management infrastructure, an investment that will help the company "deliver optimal benefit" to its customers, says executive.
Concept Life Sciences has teamed up with the UK-based bioanalytical contract research organization (CRO) Alderley Analytical to provide customers with bioanalytical and DMPK study services.
PPD and Quotient Sciences have announced a new collaboration to accelerate pediatric drug development – as developing age-appropriate medicinal formulations will continue to be a focus of regulators, clinicians, and parents, says PPD senior VP.
Massachusetts biopharma companies received $2.9bn in venture capital investment in 2016 – and as pressure continues to accelerate the drug development process, manufacturers will continue to turn to CROs and CMOs, says MassBio.
LabCorp’s Covance has launched a new dedicated offering for biotech, medical device, and diagnostic companies following its purchase of Chiltern in 2017.
Sekisui XenoTech hired in record numbers in 2017 as it anticipates 10% or higher growth over the next couple of years fueled by demand for drug-drug interaction studies.
Specialty reagent provider Maravai LifeSciences has acquired Glen Research Corporation to provide more comprehensive solutions to its customers, says VP.
JSR Corporation has acquired Crown Bioscience for more than $405m – the company’s largest investment to date as it turns its attention towards preclinical support for biopharma, says Life Sciences president.
Outsourcing models examined, market shifts scrutinized, and trial tribulations analyzed – take a look back at some of the top reports published in 2017.
By Sudip S. Parikh, PhD, senior vice president & managing director, DIA Americas
The healthcare product development ecosystem is undergoing massive changes. Significant transformations are underway in how drugs and medical devices are researched, developed, manufactured, and approved.
Apprentice has raised $2.5m in venture funding for its augmented reality solution, Affinity, which is designed to improve productivity, audit readiness quality, and safety within pharmaceutical lab and research environments, says CEO.
Pharmaceutical companies should share their outsourcing strategy across the company in order to ensure success, says panel discussing the benefits and challenges of working with contract organizations.
The Tri-Institutional Therapeutics Discovery Institute, Inc. will use ChemDiv's proprietary discovery chemistry platform to advance its research and development (R&D) pipeline.
Servier recently announced $7.5m for new technology, is doubling capacity at its Chinese facility, and is investing $58m to support biologics – a few projects among the company's effort to increase productivity as the industry demands a faster time-to-market.
Citoxlab Group has acquired Xenometrics, a non-clinical contract research organization (CRO), as client requests continue to increase, says company president.
Concept Life Sciences has acquired Aquila BioMedical, citing the CRO’s specific skill set, which will allow the company to provide services in areas “not previously accessible,” says executive chairman.
Sponsors using a single-source outsourcing partner could potentially save up to $45m through reduced time to market, according to a recent Tufts study.
Pharmaceutical companies are more likely than their suppliers to cite cost improvement over time as the most effective metric for measuring supplier performance, according to a recent report.
The VWR Science Portal provides customers with access to the Scientist.com supplier network, including more than 2,200 contract research organizations (CROs).
Pharma and diagnostic partners will gain access to a human cancer biospecimens and clinical data from patients to power clinical and translational research, says CRO.
AMRI has been acquired by a private equity firm and has already begun its search for “the next couple of acquisitions,” says its CEO – and the shopping list is long.
The mid-size contract research organization (CRO) sector continues to evolve and surprise experts with rich valuations – and what seems to be a never ending list of transactions.
Eurofins Pharma Bioanalytical Services has launched a consulting program to support clients conducting large molecule preclinical and clinical studies.
